Walvax Biotechnology Co., Ltd. (SHE:300142)

China flag China · Delayed Price · Currency is CNY
11.71
+0.04 (0.34%)
At close: Dec 5, 2025
-18.11%
Market Cap 18.73B
Revenue (ttm) 2.40B
Net Income (ttm) 49.24M
Shares Out 1.60B
EPS (ttm) 0.03
PE Ratio 380.31
Forward PE 53.84
Dividend 0.01 (0.09%)
Ex-Dividend Date May 28, 2025
Volume 18,120,930
Average Volume 37,320,015
Open 11.67
Previous Close 11.67
Day's Range 11.51 - 11.73
52-Week Range 9.70 - 15.12
Beta 0.44
RSI 39.98
Earnings Date Apr 9, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The... [Read more]

Sector Healthcare
Founded 2001
Employees 2,388
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300142
Full Company Profile

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.

Financial Statements

News

There is no news available yet.